author-photo

Enriqueta Felip

Hebron University
University of Barcelona
Autonomous University of Barcelona

655

Papers

40986

Citations

Citation Trend

Filter By

Papers (655) Sort By

Journal Conference Others

Transcriptomics in Tumor and Normal Tissues and Precision Oncology Algorithms Identify Early-Stage NSCLC Patients with High Risk of Post-Surgery Recurrence Who May Benefit from Adjuvant Therapies

2021 Social Science Research Network
Show All
- Source
- Cite
- Save
Citations (0)
Immune response after vaccination against SARS-COV-2 in lung cancer (LC) patients (p). Prospective study in the Medical Oncology Department at the Catalan Institute of Oncology-Badalona, Spain: COVID-lung vaccine

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

2021 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (0)
1025TiP SOLTI-1904: Efficacy of spartalizumab across multiple cancer-types in patients with PD1-high mRNA expressing tumors defined by a single and pre-specified cutoff (ACROPOLI)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.

2021 Targeted Oncology
Show All
- Source
- Cite
- Save
Citations (2)
A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Future care for long-term cancer survivors: towards a new model.

2021 Clinical & Translational Oncology
Show All
- Source
- Cite
- Save
Citations (0)
532P Phase Ib study evaluating BI 836880 (VEGF/Ang2 nanobody) in combination with ezabenlimab (BI 754091; anti-PD-1 antibody) in patients with solid tumours

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)